# Verdict: radiation_pneumonitis.md (Wave 8) — RE-VERIFICATION after rewrite

## 1. DOSE LEAK
None. Grepped whole file for Gy/mg/AUC/V20/dose: the sole prior offender (line 24 old draft: "20 Gy" V20 metric, "30% to 35%", "under about 20%") is now de-numbered to qualitative language: "risk rises with the mean lung dose and with the volume of lung exposed to higher radiation doses, and radiation-oncology dose-volume planning aims to keep this exposure below consensus thresholds to limit pneumonitis risk." No chemo drug dose (mg/mg-m2/AUC) or numbered schedule anywhere either. Remaining numbers in the doc (5%-50% incidence, 0-18mo onset, peak ~2mo, "~10% or lower" recent-series rate, imaging timeline 1-6mo/4-12mo/6mo-years) are epidemiology/timing figures, not treatment or planning doses.

## 2. UNGROUNDED / MISLABELLED CLAIMS
None found.
- Verified against DeVita p.68408-68427 ("Radiation Pneumonitis and Pulmonary Fibrosis"): incidence 5%-50%, onset 0-18mo/peak 2mo, presentation (cough/dyspnea/fever/fatigue), imaging timeline (ground-glass 1-6mo, consolidation 4-12mo, fibrosis 6mo-years, early changes in higher-dose region), SBRT-vs-conventional volume risk, lower-lung-field risk, age/concurrent-chemo risk naming docetaxel/gemcitabine/carboplatin+paclitaxel, glucocorticoid first-line with slow taper, rule-out-infection-first, no proven fibrosis-reversing therapy (incl. steroids), prophylactic antibiotics/anticoagulants ineffective — all verbatim/near-verbatim matches, correctly attributed to DeVita.
- "More recent series ... rates around 10% or lower" independently checked against a separate DeVita passage (~line 72992-72998, RP rate ~10% or lower with image-guided planning) — correctly attributed to DeVita even though from a different section; not mislabeled.
- Every claim not in DeVita is explicitly tagged "(general oncology standard, not from DeVita's section on this disease)": mild-disease observation (line 7), steroid-sparing immunosuppression escalation (line 16), distinguishing immune-related pneumonitis on checkpoint inhibitors (line 26), tracking oxygenation/pulse-ox (line 32). None passed off as DeVita content.
- No specific trial names, drug doses, response-rate statistics, or fibrosis-reversal/mortality numbers asserted.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th ed." — name only, no page numbers. Correct format.

## 4. VERDICT
CLEAN (ready for R1 re-review). The single blocking issue from the prior verdict (numeric V20/20 Gy dose-volume metric) has been resolved by de-numbering to qualitative language; no new issues introduced by the rewrite.
